Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03915405
Title KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Kyowa Kirin Pharmaceutical Development, Inc.
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

urethra transitional cell carcinoma

transitional cell carcinoma

Therapies

Avelumab + KHK2455

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.